Learning Objectives:

1.       DELIVER Progress in Heart Failure with Preserved Or Mildly Reduced Ejection Fraction (HFpEF/HFmEF)

2.       Review Results of the DELIVER Randomized Control Trial

3.       Assess The Unique Role of SGLT-2 Inhibitors In Patients with HFpEF and HFmEF

 Faculty Disclosure:

Scott David Solomon, MD, Presenter,

Grants and Research for HF Research:   Actelion, Alnylam, Amgen,AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, US2.AI

Consultant, HF Research:   Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boeringer-Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Puretech Health

Faculty does not plan to discuss the uses of an investigational product.